Vaccines

Editorial

Jump to: Research, Review, Other

4 pages, 194 KiB

Open AccessEditorial

Special Issue on ‘Coronavirus: Vaccines and Other Therapeutics’ (2020–2021)

by Sankar Basu

Vaccines 2021, 9(10), 1083; https://doi.org/10.3390/vaccines9101083 - 26 Sep 2021

Cited by 1 | Viewed by 1942

Abstract

As is well known, the emergence of SARS-CoV-2 ever since late 2019 [...] Full article

(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)

► Show Figures

Graphical abstract

Research

Jump to: Editorial, Review, Other

20 pages, 5730 KiB

Open AccessArticle

Effectiveness of Comirnaty^® Vaccine and Correlates of Immunogenicity and Adverse Reactions: A Single-Center Prospective Case Series Study

by Diego Fernández-Lázaro, Manuel Garrosa, Nerea Sánchez-Serrano, Evelina Garrosa, Elena Jiménez-Callejo, María Dolores Pardo Yanguas, Juan Mielgo-Ayuso and Jesús Seco-Calvo

Vaccines 2022, 10(8), 1170; https://doi.org/10.3390/vaccines10081170 - 22 Jul 2022

Cited by 2 | Viewed by 2227

Abstract

The literature suggests that real-world data on the effectiveness and safety of the BNT162b2 vaccine depend on the characteristics of the vaccinated volunteers. The purpose of this study was to evaluate antibody responses and kinetics, established association with sociodemographic and clinical characteristics, and [...] Read more.

The literature suggests that real-world data on the effectiveness and safety of the BNT162b2 vaccine depend on the characteristics of the vaccinated volunteers. The purpose of this study was to evaluate antibody responses and kinetics, established association with sociodemographic and clinical characteristics, and adverse reactions after complete vaccination with the BNT162b2 vaccine. A single-center prospective case series study was conducted with 112 eligible volunteers who were institutionalized elderly and health care workers with had a negative anti-SARS-CoV-2 IgG test prior to receiving the first dose of vaccine. At least one serological antibody test after each dose of vaccine was performed. Volunteers with a positive SARS-CoV-2 PCR test before vaccination were excluded. A chemiluminescent immunoassay anti-S1 antibody assay performed a serological evaluation. Both vaccine doses elicited positive IgG antibodies 3799.0 ± 2503.0 AU/mL and 8212.0 ± 4731.0 AU/mL after 20 days of the first and second doses of BNT162b2, respectively. Comirnaty^® vaccine induced an immune response with antibody production against SARS-CoV-2 in 100% of participants, regardless of age (Spearman rho = −0.10, p-value = 0.312), body mass index (Spearman rho = 0.05, p-value = 0.640), blood group first dose (p-value for Kruskal–Wallis test = 0.093) and second dose (p-value for Kruskal–Wallis test = 0. 268), number of drugs (Spearman rho = −0.07, p-value = 0.490), and number of chronic diseases first dose (p-value for Kruskal–Wallis test = 0.632) and second dose (p-value for Kruskal–Wallis test = 0.510). IgG antibodies to SARS-CoV-2 were intensely elevated after the second administration of the BNT162b2 vaccine. The higher the titer of anti-peptide IgG antibodies generated after the first dose of vaccine, the higher the titer generated by the second dose of vaccine (Spearman rho = 0.86, p-value < 0.001) and the total antibody titer (Spearman rho = 0.93, p-value < 0.001). Furthermore, no serious adverse effects were reported among participants, although mild to moderate adverse effects (local or systemic) were reported after both doses of the BNT162b2 vaccine, being more frequent after the first dose of the vaccine. No participants showed a positive PCR. The BNT162b2 vaccine induces a robust and rapid antibody response regardless of participant characteristics. The second dose might be especially important because of the increased immunogenicity it produces and the possible temporal distancing of the interval between doses. In general, the vaccines were well tolerated. Full article

(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)

► Show Figures

Figure 1

11 pages, 1299 KiB

Open AccessArticle

Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination

by Katharina Grikscheit, Holger F. Rabenau, Zahra Ghodratian, Marek Widera, Alexander Wilhelm, Tuna Toptan Grabmair, Sebastian Hoehl, Emily Layer, Fabian Helfritz and Sandra Ciesek

Vaccines 2022, 10(7), 1163; https://doi.org/10.3390/vaccines10071163 - 21 Jul 2022

Cited by 4 | Viewed by 3321

Abstract

The emergence of SARS-CoV-2 Omicron subvariants prompted countries to call for accelerated booster vaccinations to limit disease and transmission. Here, we characterized correlates of protection over time after the second booster or after Omicron BA.1 infection comparing variants of concern (VOCs). Sera from [...] Read more.

The emergence of SARS-CoV-2 Omicron subvariants prompted countries to call for accelerated booster vaccinations to limit disease and transmission. Here, we characterized correlates of protection over time after the second booster or after Omicron BA.1 infection comparing variants of concern (VOCs). Sera from subjects before and two and seven weeks after the second booster or after Omicron infection were examined for the level of Spike receptor-binding-domain (RBD)-specific antibodies. Furthermore, neutralizing antibodies (nABs) were characterized in in vitro neutralization assays comparing the variants of concern Alpha, Beta, Delta, and Omicron BA.1 and BA.2 against the ancestral strain B.1. Here, the second booster resulted in an increase in anti-RBD-IgG-antibodies, remaining nearly constant over time, accompanied by an increase in nABs against B.1 and the VOCs Alpha, Beta, Delta, and Omicron BA.1 and BA.2. However, compared to B.1, the neutralizing capacity against the Omicron subvariants remained low and was limited after the second booster vaccination. This indicates that antibody-mediated protection against infection with this VOC is unlikely, as evidenced by the fact that three individuals of our study cohort became infected with Omicron BA.1 after the second booster. T cell activation was measured by interferon-gamma release assays in a subgroup of subjects and was increased in all subjects tested after the second booster vaccination, correlating with the amount of Spike-specific antibodies. In subjects with Omicron BA.1 breakthrough infection, a significant increase in nABs to all VOCs studied was observed independently of booster vaccinations. Taken together, our data indicate that a second booster or Omicron BA.1 infection mediate a substantial increase in anti-Spike IgG antibodies; however, infection with Omicron BA.1 induced a stronger increase in neutralizing antibodies against the different VOCs Full article

(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)

► Show Figures

Figure 1

18 pages, 13445 KiB

Open AccessArticle

The Existence of at Least Three Genomic Signature Patterns and at Least Seven Subtypes of COVID-19 and the End of the Disease

by Zhengjun Zhang

Vaccines 2022, 10(5), 761; https://doi.org/10.3390/vaccines10050761 - 11 May 2022

Cited by 4 | Viewed by 2879

Abstract

Hoping to find genomic clues linked to COVID-19 and end the pandemic has driven scientists’ tremendous efforts to try all kinds of research. Signs of progress have been achieved but are still limited. This paper intends to prove the existence of at least [...] Read more.

Hoping to find genomic clues linked to COVID-19 and end the pandemic has driven scientists’ tremendous efforts to try all kinds of research. Signs of progress have been achieved but are still limited. This paper intends to prove the existence of at least three genomic signature patterns and at least seven subtypes of COVID-19 driven by five critical genes (the smallest subset of genes) using three blood-sampled datasets. These signatures and subtypes provide crucial genomic information in COVID-19 diagnosis (including ICU patients), research focuses, and treatment methods. Unlike existing approaches focused on gene fold-changes and pathways, gene-gene nonlinear and competing interactions are the driving forces in finding the signature patterns and subtypes. Furthermore, the method leads to high accuracy with hospitalized patients, showing biological and mathematical equivalences between COVID-19 status and the signature patterns and a methodological advantage over other methods that cannot lead to high accuracy. As a result, as new biomarkers, the new findings and genomic clues can be much more informative than other findings for interpreting biological mechanisms, developing the second (third) generation of vaccines, antiviral drugs, and treatment methods, and eventually bringing new hopes of an end to the pandemic. Full article

(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)

► Show Figures

Figure 1

14 pages, 771 KiB

Open AccessArticle

Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and during the Omicron Wave

by Cecilia Acuti Martellucci, Maria Elena Flacco, Graziella Soldato, Giuseppe Di Martino, Roberto Carota, Antonio Caponetti and Lamberto Manzoli

Vaccines 2022, 10(5), 662; https://doi.org/10.3390/vaccines10050662 - 22 Apr 2022

Cited by 21 | Viewed by 6764

Abstract

We performed a cohort analysis of the entire population of Abruzzo, Italy, to evaluate the real-world effectiveness of SARS-CoV-2 vaccines against infection, COVID-19 hospitalization or death, over time and during the Omicron wave. All resident or domiciled subjects were included, and official vaccination, [...] Read more.

We performed a cohort analysis of the entire population of Abruzzo, Italy, to evaluate the real-world effectiveness of SARS-CoV-2 vaccines against infection, COVID-19 hospitalization or death, over time and during the Omicron wave. All resident or domiciled subjects were included, and official vaccination, COVID-19, demographic, hospital and co-pay exemption datasets were extracted up to 18 February 2022. Multivariable analyses were adjusted for age, gender, hypertension, diabetes, major cardio- and cerebrovascular events, COPD, kidney diseases, and cancer. During the follow-up (average 244 days), 252,365 subjects received three vaccine doses (of BNT162b2, ChAdOx1 nCoV-19, mRNA-1273 or JNJ-78436735), 684,860 two doses, 29,401 one dose, and 313,068 no dose. Overall, 13.4% of the individuals were infected with SARS-CoV-2 (n = 170,761); 1.1% of them had severe COVID-19, and 0.6% died. Compared with the unvaccinated, those receiving two or three vaccine doses showed an 80% to 90% lower risk of COVID-19 hospitalization or death. Protection decreased during the Omicron wave and six months after the last dose, but it remained substantial. Lethal disease was uncommon during the Omicron wave and in the young population, even among the unvaccinated. Some of the current policies may need a re-evaluation in light of these findings. The results from the Omicron wave will inevitably require confirmation. Full article

(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)

► Show Figures

Figure 1

37 pages, 13186 KiB

Open AccessArticle

Capturing a Crucial ‘Disorder-to-Order Transition’ at the Heart of the Coronavirus Molecular Pathology—Triggered by Highly Persistent, Interchangeable Salt-Bridges

by Sourav Roy, Prithwi Ghosh, Abhirup Bandyopadhyay and Sankar Basu

Vaccines 2022, 10(2), 301; https://doi.org/10.3390/vaccines10020301 - 16 Feb 2022

Cited by 7 | Viewed by 3867

Abstract

The COVID-19 origin debate has greatly been influenced by genome comparison studies of late, revealing the emergence of the Furin-like cleavage site at the S1/S2 junction of the SARS-CoV-2 Spike (FLCS_Spike) containing its ₆₈₁PRRAR₆₈₅ motif, absent in other related [...] Read more.

The COVID-19 origin debate has greatly been influenced by genome comparison studies of late, revealing the emergence of the Furin-like cleavage site at the S1/S2 junction of the SARS-CoV-2 Spike (FLCS_Spike) containing its ₆₈₁PRRAR₆₈₅ motif, absent in other related respiratory viruses. Being the rate-limiting (i.e., the slowest) step, the host Furin cleavage is instrumental in the abrupt increase in transmissibility in COVID-19, compared to earlier onsets of respiratory viral diseases. In such a context, the current paper entraps a ‘disorder-to-order transition’ of the FLCS_Spike (concomitant to an entropy arrest) upon binding to Furin. The interaction clearly seems to be optimized for a more efficient proteolytic cleavage in SARS-CoV-2. The study further shows the formation of dynamically interchangeable and persistent networks of salt-bridges at the Spike–Furin interface in SARS-CoV-2 involving the three arginines (R682, R683, R685) of the FLCS_Spike with several anionic residues (E230, E236, D259, D264, D306) coming from Furin, strategically distributed around its catalytic triad. Multiplicity and structural degeneracy of plausible salt-bridge network archetypes seem to be the other key characteristic features of the Spike–Furin binding in SARS-CoV-2, allowing the system to breathe—a trademark of protein disorder transitions. Interestingly, with respect to the homologous interaction in SARS-CoV (2002/2003) taken as a baseline, the Spike–Furin binding events, generally, in the coronavirus lineage, seems to have preference for ionic bond formation, even with a lesser number of cationic residues at their potentially polybasic FLCS_Spike patches. The interaction energies are suggestive of characteristic metastabilities attributed to Spike–Furin interactions, generally to the coronavirus lineage, which appears to be favorable for proteolytic cleavages targeted at flexible protein loops. The current findings not only offer novel mechanistic insights into the coronavirus molecular pathology and evolution, but also add substantially to the existing theories of proteolytic cleavages. Full article

(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)

► Show Figures

Figure 1

12 pages, 601 KiB

Open AccessArticle

Is It All a Conspiracy? Conspiracy Theories and People’s Attitude to COVID-19 Vaccination

by Zheng Yang, Xi Luo and Hepeng Jia

Vaccines 2021, 9(10), 1051; https://doi.org/10.3390/vaccines9101051 - 22 Sep 2021

Cited by 52 | Viewed by 11915

Abstract

A large body of research has found that people’s beliefs in conspiracy theories about infectious diseases negatively impacts their health behaviors concerning vaccination. Conspiracy belief-based vaccination hesitancy has become more rampant after the global outbreak of COVID-19. However, some important questions remain unanswered. [...] Read more.

A large body of research has found that people’s beliefs in conspiracy theories about infectious diseases negatively impacts their health behaviors concerning vaccination. Conspiracy belief-based vaccination hesitancy has become more rampant after the global outbreak of COVID-19. However, some important questions remain unanswered. For instance, do different versions of conspiracy theories—particularly conspiracy theories about the origin of the epidemic (e.g., that the SARS-CoV-2 leaked from a Wuhan virology laboratory or that the virus was of foreign origin) and the general theories about vaccine conspiracies (e.g., pharmaceutical companies covered up the danger of vaccines or people are being deceived about the effectiveness of vaccines)—have the same effect on vaccination intentions? Through a national survey adopting quota sampling in China, the current study tested the relationship between people’s conspiracy beliefs and their intention to receive the COVID-19 vaccination. The findings show that people’s embrace of conspiracy theories did indeed affect their intention to take COVID-19 shots. However, only conspiracy theories related to vaccines had a significant impact, while belief in more general theories about COVID-19 did not significantly affect vaccination intentions. People’s knowledge of vaccines (vaccine literacy) played an important role in this relationship. People with lower beliefs in vaccines conspiracy theories and higher levels of vaccine literacy were more likely to receive the COVID-19 vaccination. Full article

(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)

► Show Figures

Figure 1

16 pages, 3891 KiB

Open AccessArticle

Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains

by Ki-Back Chu, Hae-Ji Kang, Keon-Woong Yoon, Hae-Ahm Lee, Eun-Kyung Moon, Beom-Ku Han and Fu-Shi Quan

Vaccines 2021, 9(8), 920; https://doi.org/10.3390/vaccines9080920 - 18 Aug 2021

Cited by 17 | Viewed by 4263

Abstract

The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic had brought disastrous consequences throughout the entire world. While several manufactured vaccines have been approved for emergency use, continuous efforts to generate novel vaccines are needed. In this study, we developed SARS-CoV-2 virus-like particles [...] Read more.

The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic had brought disastrous consequences throughout the entire world. While several manufactured vaccines have been approved for emergency use, continuous efforts to generate novel vaccines are needed. In this study, we developed SARS-CoV-2 virus-like particles (VLPs) containing the full length of spike (S) glycoprotein (S full), S1, or S2 together with the influenza matrix protein 1 (M1) as a core protein. Successfully constructed VLPs expressing the S full, S1, and S2 via Sf9 cell transfections were confirmed and characterized by Western blot and transmission electron microscopy (TEM). VLP immunization in mice induced higher levels of spike protein-specific IgG and its subclasses compared to naïve control, with IgG2a being the most predominant subclass. S full and S1 immune sera elicited virus-neutralizing activities, but these were not strong enough to fully inhibit receptor–ligand binding of the SARS-CoV-2. Neutralizing activities were not observed from the S2 VLP immune sera. Overall, our findings revealed that S full or S1 containing VLPs can be developed into effective vaccines. Full article

(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)

► Show Figures

Figure 1

Review

Jump to: Editorial, Research, Other

24 pages, 1278 KiB

Open AccessReview

COVID-19 Vaccine: Between Myth and Truth

by Pier Paolo Piccaluga, Antonio Di Guardo, Anna Lagni, Virginia Lotti, Erica Diani, Mohsen Navari and Davide Gibellini

Vaccines 2022, 10(3), 349; https://doi.org/10.3390/vaccines10030349 - 23 Feb 2022

Cited by 13 | Viewed by 6266

Abstract

Since December 2019, a pandemic caused by the newly identified SARS-CoV-2 spread across the entire globe, causing 364,191,494 confirmed cases of COVID-19 to date. SARS-CoV-2 is a betacoronavirus, a positive-sense, single-stranded RNA virus with four structural proteins: spike (S), envelope (E), membrane (M), [...] Read more.

Since December 2019, a pandemic caused by the newly identified SARS-CoV-2 spread across the entire globe, causing 364,191,494 confirmed cases of COVID-19 to date. SARS-CoV-2 is a betacoronavirus, a positive-sense, single-stranded RNA virus with four structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N). The S protein plays a crucial role both in cell binding and in the induction of a strong immune response during COVID-19 infection. The clinical impact of SARS-CoV-2 and its spread led to the urgent need for vaccine development to prevent viral transmission and to reduce the morbidity and mortality associated with the disease. Multiple platforms have been involved in the rapid development of vaccine candidates, with the S protein representing a major target because it can stimulate the immune system, yielding neutralizing antibodies (NAbs), blocking viral entry into host cells, and evoking T-cell immune responses. To date, 178 SARS-CoV-2 vaccine candidates have been challenged in clinical trials, of which 33 were approved by various national regulatory agencies. In this review, we discuss the FDA- and/or EMA-authorized vaccines that are mostly based on mRNA or viral vector platforms. Furthermore, we debunk false myths about the COVID-19 vaccine as well as discuss the impact of viral variants and the possible future developments. Full article

(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)

► Show Figures

Figure 1

16 pages, 1599 KiB

Open AccessReview

Plant-Based Vaccines in Combat against Coronavirus Diseases

by Benita Ortega-Berlanga and Tomasz Pniewski

Vaccines 2022, 10(2), 138; https://doi.org/10.3390/vaccines10020138 - 18 Jan 2022

Cited by 14 | Viewed by 4776

Abstract

Coronavirus (CoV) diseases, including Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) have gained in importance worldwide, especially with the current COVID-19 pandemic caused by SARS-CoV-2. Due to the huge global demand, various types of vaccines have been developed, such [...] Read more.

Coronavirus (CoV) diseases, including Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) have gained in importance worldwide, especially with the current COVID-19 pandemic caused by SARS-CoV-2. Due to the huge global demand, various types of vaccines have been developed, such as more traditional attenuated or inactivated viruses, subunit and VLP-based vaccines, as well as novel DNA and RNA vaccines. Nonetheless, emerging new COVID-19 variants are necessitating continuous research on vaccines, including these produced in plants, either via stable expression in transgenic or transplastomic plants or transient expression using viral vectors or agroinfection. Plant systems provide low cost, high scalability, safety and capacity to produce multimeric or glycosylated proteins. To date, from among CoVs antigens, spike and capsid proteins have been produced in plants, mostly using transient expression systems, at the additional advantage of rapid production. Immunogenicity of plant-produced CoVs proteins was positively evaluated after injection of purified antigens. However, this review indicates that plant-produced CoVs proteins or their carrier-fused immunodominant epitopes can be potentially applied also as mucosal vaccines, either after purification to be administered to particular membranes (nasal, bronchus mucosa) associated with the respiratory system, or as oral vaccines obtained from partly processed plant tissue. Full article

(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)

► Show Figures

Figure 1

8 pages, 695 KiB

Open AccessReview

How Does Severe Acute Respiratory Syndrome-Coronavirus-2 Affect the Brain and Its Implications for the Vaccines Currently in Use

by Philip R. Oldfield, Jennifer Hibberd and Byram W. Bridle

Vaccines 2022, 10(1), 1; https://doi.org/10.3390/vaccines10010001 - 21 Dec 2021

Cited by 7 | Viewed by 16782

Abstract

This mini-review focuses on the mechanisms of how severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) affects the brain, with an emphasis on the role of the spike protein in patients with neurological symptoms. Following infection, patients with a history of neurological complications may be at [...] Read more.

This mini-review focuses on the mechanisms of how severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) affects the brain, with an emphasis on the role of the spike protein in patients with neurological symptoms. Following infection, patients with a history of neurological complications may be at a higher risk of developing long-term neurological conditions associated with the α-synuclein prion, such as Parkinson’s disease and Lewy body dementia. Compelling evidence has been published to indicate that the spike protein, which is derived from SARS-CoV-2 and generated from the vaccines currently being employed, is not only able to cross the blood–brain barrier but may cause inflammation and/or blood clots in the brain. Consequently, should vaccine-induced expression of spike proteins not be limited to the site of injection and draining lymph nodes there is the potential of long-term implications following inoculation that may be identical to that of patients exhibiting neurological complications after being infected with SARS-CoV-2. However, further studies are needed before definitive conclusions can be made. Full article

(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)

► Show Figures

Figure 1

25 pages, 3499 KiB

Open AccessReview

Parents’ Decisions to Vaccinate Children against COVID-19: A Scoping Review

by Fengming Pan, Hongyu Zhao, Stephen Nicholas, Elizabeth Maitland, Rugang Liu and Qingzhen Hou

Vaccines 2021, 9(12), 1476; https://doi.org/10.3390/vaccines9121476 - 14 Dec 2021

Cited by 60 | Viewed by 6159

Abstract

Since 2019, the COVID-19 pandemic has resulted in sickness, hospitalizations, and deaths of the old and young and impacted global social and economy activities. Vaccination is one of the most important and efficient ways to protect against the COVID-19 virus. In a review [...] Read more.

Since 2019, the COVID-19 pandemic has resulted in sickness, hospitalizations, and deaths of the old and young and impacted global social and economy activities. Vaccination is one of the most important and efficient ways to protect against the COVID-19 virus. In a review of the literature on parents’ decisions to vaccinate their children, we found that widespread vaccination was hampered by vaccine hesitancy, especially for children who play an important role in the coronavirus transmission in both family and school. To analyze parent vaccination decision-making for children, our review of the literature on parent attitudes to vaccinating children, identified the objective and subjective influencing factors in their vaccination decision. We found that the median rate of parents vaccinating their children against COVID-19 was 59.3% (IQR 48.60~73.90%). The factors influencing parents’ attitudes towards child vaccination were heterogeneous, reflecting country-specific factors, but also displaying some similar trends across countries, such as the education level of parents. The leading reason in the child vaccination decision was to protect children, family and others; and the fear of side effects and safety was the most important reason in not vaccinating children. Our study informs government and health officials about appropriate vaccination policies and measures to improve the vaccination rate of children and makes specific recommendations on enhancing child vaccinate rates. Full article

(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)

► Show Figures

Figure 1

Other

Jump to: Editorial, Research, Review

6 pages, 1156 KiB

Open AccessBrief Report

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants

by Gabriele Anichini, Chiara Terrosi, Gianni Gori Savellini, Claudia Gandolfo, Federico Franchi and Maria Grazia Cusi

Vaccines 2021, 9(5), 517; https://doi.org/10.3390/vaccines9050517 - 18 May 2021

Cited by 16 | Viewed by 4477

Abstract

Due to their increased transmissibility, three variants of high concern have emerged in the United Kingdom (also known as B.1.1.7 lineage or VOC-202012/01), South Africa (B.1.351 lineage), and Brazil (P1 lineage) with multiple substitutions in the spike protein. Since neutralizing antibodies elicited by [...] Read more.

Due to their increased transmissibility, three variants of high concern have emerged in the United Kingdom (also known as B.1.1.7 lineage or VOC-202012/01), South Africa (B.1.351 lineage), and Brazil (P1 lineage) with multiple substitutions in the spike protein. Since neutralizing antibodies elicited by vaccination are likely considered as correlates of protection for SARS-CoV-2 infection, it is important to analyze whether vaccinees with mRNA BNT162b2 are equally protected against these emerging SARS-CoV-2 variants. To this aim, we enrolled healthy subjects one month after complete vaccination with Comirnaty and evaluated the neutralizing response against the native Wuhan strain and the emerging B.1.1.7, B.1.351 and P1 lineages, by using the microneutralization assay, currently considered the gold standard test for the evaluation and detection of functional neutralizing antibodies. The most remarkable finding of this study was the significantly lower neutralizing antibody titer against B.1.351 lineage, compared to the wild-type virus. No significant differences were observed with the other two lineages. These findings provide evidence that vaccinated subjects may not be equally protected against all SARS-CoV-2 lineages. Full article

(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Coronavirus: Vaccines and Other Therapeutics

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (13 papers)

Editorial

Research

Review

Other

Further Information

Guidelines

MDPI Initiatives

Follow MDPI